Palbociclib (Ibrance) for metastatic ER+ breast cancer - NZ update

Palbociclib (brand name Ibrance) is a new medicine for advanced ER+ breast cancer that has achieved significant results in high-profile clinical trials overseas. It has been funded in New Zealand since April 2020.

Meet your panel:

Dr Richard Finn is associate professor of Medicine at the UCLA David Geffen School of Medicine. He led the PALOMA series of clinical trials for palbociclib and is considered one of the world's foremost experts on this new drug.